Antitumoral and antimetastatic effects of continuous particle-mediated cytokine gene therapy.

[1]  C. Van Waes,et al.  IL‐12‐ and IL‐2‐induced tumor regression in a new murine model of oral squamous‐cell carcinoma is promoted by expression of the CD80 co‐stimulatory molecule and interferon‐γ , 2000, International journal of cancer.

[2]  S. Mian,et al.  Selective MHC expression in tumours modulates adaptive and innate antitumour responses , 1999, Cancer Immunology, Immunotherapy.

[3]  J. Taylor‐Papadimitriou,et al.  Immunity to breast cancer in mice immunized with X-irradiated breast cancer cells modified to secrete IL-12. , 1999, Journal of immunotherapy.

[4]  B. Gückel,et al.  Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation , 1999, Cancer Gene Therapy.

[5]  A. Paller,et al.  In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. , 1999, The Journal of investigative dermatology.

[6]  H. Kittler,et al.  Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. , 1999, Human gene therapy.

[7]  W. Muller,et al.  Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors , 1998, Gene Therapy.

[8]  K. Decken,et al.  Interleukin-12 Is Essential for a Protective Th1 Response in Mice Infected with Cryptococcus neoformans , 1998, Infection and Immunity.

[9]  J. Nemunaitis,et al.  Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. , 1998, Cancer gene therapy.

[10]  D. Schadendorf,et al.  Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study , 1998, Gene Therapy.

[11]  M. Kurimoto,et al.  Antitumor Effects on Mouse Melanoma Elicited by Local Secretion of Interleukin-12 and Their Enhancement by Treatment with Interleukin-18 , 1998, Cancer investigation.

[12]  B. Gückel,et al.  Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma. , 1997, International immunology.

[13]  H. Lyerly,et al.  Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. , 1996, Surgery.

[14]  N. Yang,et al.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Zitvogel,et al.  Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors , 1996, European journal of immunology.

[16]  M. Albertini,et al.  Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer. , 1996, Cancer gene therapy.

[17]  G. Gray,et al.  B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. , 1995, Cancer gene therapy.

[18]  O. Yoshida,et al.  Induction of specific anti-tumour immunity by interferon-gamma gene-transferred murine bladder carcinoma MBT-2. , 1994, Folia biologica.